Nov 30 (Reuters) - Johnson & Johnson's Janssen unit has sued Amgen Inc over its plan to market an ulcerative colitis drug similar to J&J's Stelara, saying it would infringe two patents.
Stelara is a major seller for J&J, bringing the company nearly $2.5 billion in the third quarter of 2022. (Reporting By Brendan Pierson in New York)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
The $50 million purchase could turn into Nvidia's biggest investment.
This little-known software stock could soar as businesses spend more on generative artificial intelligence.
These two dividend payers have historically high yields and attractive businesses, even though there are some headwinds to deal with.
A month after a higher state minimum wage for fast-food workers went into effect, consumers picking up burgers and burritos at chains in the Golden State grapple with prices rising at a faster clip than in other states.
These three tech stocks look like reliable long-term winners.
“When she died, we were told by her attorney that we were responsible for the taxes and property insurance during the time when the life tennant lives in the home.”
The tobacco giant will soon be allowed to sell a proven product in a proven market.
"And that's why it was kind of shocking to see bond yields rise on a day where GDP was a big miss."